drugset / Trial / NCT06607016
A Clinical Trial With KJ103 in Anti-GBM Disease
NaSingle-groupOpen-labelTreatment
Summary
An open-label, single-arm Phase II study to evaluate the preliminary efficacy, safety, pharmacokinetics, pharmacodynamics and immunogenicity of KJ103 in patients with anti-GBM disease.
Timeline
- Start
- 2024-10-21
- Primary completion
- 2025-12-31
- Completion
- 2026-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | KJ103 | Unknown | — | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | — | — |